司库奇尤单抗治疗放射学阳性与放射学阴性中轴型脊柱关节炎的有效性:一项欧洲常规诊疗观察性研究
该研究汇总九个国家1161例接受司库奇尤单抗治疗的中轴型脊柱关节炎患者前瞻性数据,比较放射学阳性(922例)与放射学阴性(239例)患者的缓解率与药物留存率。粗分析中放射学阳性组患者报告结局缓解率及药物留存率更高,但校正年龄和性别后差异减小,校正多个混杂因素后两组缓解率和药物留存率均无显著差异。
要点
- 粗分析6个月疼痛≤2比例放射学阳性组40% vs 放射学阴性组28%(OR=1.7),BASDAI≤2为37% vs 25%(OR=1.8)。
- 粗分析24个月药物留存率放射学阳性组66% vs 放射学阴性组58%,HR 0.73(参照:放射学阳性组)。
- 校正多个混杂因素后,两组缓解率与药物留存率均无显著差异。
核心结论
- 欧洲司库奇尤单抗治疗患者粗缓解率和药物留存率在放射学阳性中轴型脊柱关节炎中高于放射学阴性中轴型脊柱关节炎。
- 校正分析中司库奇尤单抗有效性在两组相似,提示观察到的差异与放射学状态以外的因素有关。
研究设计与样本
- 前瞻性收集九个国家已知放射学状态的中轴型脊柱关节炎患者数据并汇总,共纳入1161例接受司库奇尤单抗治疗的患者(放射学阳性/放射学阴性:922/239)。
- 计算司库奇尤单抗治疗6/12/24个月后基于患者报告结局的缓解率,并用logistic回归和Cox回归模型比较两组缓解率与药物留存率(未校正/校正年龄+性别/校正多个混杂因素)。
主要发现
- 基线时放射学阳性患者较放射学阴性患者病程更长、C反应蛋白更高、男性及HLA-B27阳性比例更高、既往生物制剂或靶向合成改善病情抗风湿药使用更少,而患者报告结局基本相似。
- 粗分析6个月疼痛≤2比例放射学阳性组40% vs 放射学阴性组28%(OR=1.7),BASDAI≤2比例37% vs 25%(OR=1.8)。
- 粗分析24个月药物留存率放射学阳性组66% vs 放射学阴性组58%,HR 0.73(参照:放射学阳性组)。
- 两组达到ASDAS非活动性疾病比例均低,放射学阴性组尤其低(6个月:11%/8%)。
- 校正年龄+性别后差异减小,校正多个混杂因素后两组缓解率和药物留存率均无显著差异。
关键数值与推荐
- 缓解定义基于患者报告结局:疼痛数字评定量表(0-10)≤2、BASDAI≤2、ASDAS非活动性疾病<1.3。
- 评估时间点为司库奇尤单抗治疗6/12/24个月后。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To compare the treatment effectiveness of secukinumab in radiographic (r) versus non-radiographic (nr) axial spondyloarthritis (axSpA) patients treated in routine care across Europe. METHODS: Prospectively collected data on secukinumab-treated axSpA patients with known radiographic status were pooled from nine countries.Remission rates based on patient-reported outcomes (PROs; Numeric Rating Scale (0-10), for example, pain ≤2/Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) ≤2 and Ankylosing Spondylitis Disease Activity Score (ASDAS) inactive disease (ID) <1.3 after 6/12/24 months of secukinumab treatment were calculated.Remission and drug retention rates in r-axSpA versus nr-axSpA patients were compared by logistic and Cox regression models (unadjusted/adjusted for age+sex/adjusted for multiple confounders). RESULTS: Overall, 1161 secukinumab-treated patients were included (r-axSpA/nr-axSpA: 922/239). At baseline, r-axSpA patients had longer disease duration and higher C reactive protein, were more often male and HLA-B27 positive and had received fewer prior biological or targeted synthetic disease-modifying antirheumatic drugs compared with nr-axSpA patients, whereas PROs were largely similar.During follow-up, crude PRO remission rates were significantly higher in r-axSpA compared with nr-axSpA patients (6 months: pain≤2: 40%/28%, OR=1.7; BASDAI≤2: 37%/25%, OR=1.8), as were drug retention rates (24 months: 66%/58%, HR 0.73 (ref: r-axSpA)). Proportions of patients achieving ASDAS ID were low for both groups, particularly nr-axSpA (6 months: 11%/8%).However, when adjusting for age+sex, these differences diminished, and after adjusting for multiple confounders, no significant between-group differences remained for either remission or drug retention rates. CONCLUSION: Crude remission/drug retention rates in European secukinumab-treated patients were higher in r-axSpA compared with nr-axSpA patients. In adjusted analyses, secukinumab effectiveness was similar in both groups, suggesting that observed differences were related to factors other than radiographic status.
引用
- Christiansen SN, Horskjær Rasmussen S, Ostergaard M, et al. Effectiveness of secukinumab in radiographic and non-radiographic axial spondyloarthritis: a European routine-care observational study. RMD Open. 2024. PMID: 39053949. doi:10.1136/rmdopen-2024-004166
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。